Therapeutic approach of hepatic sarcoidosis

@article{Cremers2012TherapeuticAO,
  title={Therapeutic approach of hepatic sarcoidosis},
  author={J. Cremers and M. Drent and R. Baughman and P. Wijnen and G. Koek},
  journal={Current Opinion in Pulmonary Medicine},
  year={2012},
  volume={18},
  pages={472–482}
}
Purpose of reviewSurveillance of hepatic involvement in sarcoidosis has not been standardized. Therefore, management of hepatic involvement is a clinical challenge. This review analyses published data on the pharmacological treatment of hepatic sarcoidosis. Recent findingsOnly 5–30% of patients with hepatic sarcoidosis display symptoms. Occasionally, it has a rapid progressive course with serious complications, stressing an appropriate and carefully timed therapeutic approach. Because… Expand
A Comprehensive Review of Hepatic Sarcoid.
TLDR
The mainstays of hepatic sarcoid treatment have involved steroids and more recently, ursodeoxycholic acid; however, novel immunomodulatory agents provide new possibilities for management. Expand
Hepatic Sarcoidosis
TLDR
Hepatic sarcoidosis is a multisystem disease characterized by the presence of non-caseating granulomas in affected organs and the majority of cases are discovered incidentally, frequently by the finding of elevated liver enzymes. Expand
Sarcoidosis Masquerading as Long-Standing Cholestasis
TLDR
This work presents an interesting case of cholestatic pattern livery injury in an outpatient setting that was eventually discovered to be hepatic sarcoidosis, and presents an opportunity to treat liver disease with a reversible cause. Expand
The Treatment of Pulmonary Sarcoidosis
TLDR
Not all therapy is equally effective in sarcoidosis; drugs such as chloroquine and thalidomide may be effective for cutaneous disease but not pulmonary disease, and some drugs seem only to be useful as steroid-sparing agents for pulmonary disease. Expand
Hepatic sarcoidosis: pathogenesis, clinical context, and treatment options
TLDR
There is a role for additional immunosuppressive therapy in cases where the initial treatment is refractory to steroids and the current body of research in regard to treatment suggests steroids to be the mainstay of therapy. Expand
Medical therapy of sarcoidosis.
TLDR
For treatment of sarcoidosis, one should develop a long-term management plan, factors to be considered include the organ involvement and severity of symptoms, and other anti-inflammatory drugs such as hydroxychloroquine. Expand
Clinical presentation and protocol for management of hepatic sarcoidosis
TLDR
The authors’ protocol for management of patients with suspected sarcoidosis of the liver without focal lesions includes a transjugular liver biopsy with portal pressure measurements to confirm the diagnosis, rule out coexisting liver diseases and to identify select patients with fibrosis or portal hypertension for consideration of immunosuppression. Expand
Extrapulmonary sarcoidosis primarily presenting as cholestatic liver disease
TLDR
A case is presented that is particularly notable for its rare presentation of NPS as a granulomatous hepatitis with cholestatic liver function tests. Expand
Gastrointestinal Involvement of Sarcoidosis
TLDR
Clinical presentations of hepatic sarcoidosis have a wide spectrum from asymptomatic mild elevation of liver chemistries to rapidly progressive cholestasis and liver failure requiring liver transplantation. Expand
Clinical Characteristics and Outcome of Hepatic Sarcoidosis: A Population-Based Study 1976–2013
TLDR
A population-based cohort of patients with incident sarcoidosis in Olmsted County, MN, USA, from 1976 to 2013 was identified and involvement of the liver by sarcoids was seen in 6% of patients, the majority of patients were asymptomatic. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 102 REFERENCES
Diagnosis and treatment of hepatic sarcoidosis
TLDR
Treatment for hepatic sarcoidosis is targeted toward alleviation of symptoms but has no curative potential at this time, and focus should be on discovering the etiology of the disease to target therapy at prevention, not cure. Expand
Extrapulmonary sarcoidosis primarily diagnosed in the liver.
TLDR
A 73-year-old patient admitted to the authors' hospital because of fatigue, weight loss, and an increased alkaline phosphatase level is described, and a liver biopsy finally confirmed the diagnosis of a systemic sarcoidosis without affection of the lung or mediastinal lymph nodes. Expand
Natural history of hepatic sarcoidosis and its response to treatment
TLDR
Sarcoidosis can cause end-stage chronic liver disease, which is often unrecognized until examination of the explanted liver, and response to conventional immunosuppression is variable and unpredictable. Expand
Sarcoidosis: clinical update.
  • U. Costabel
  • Medicine
  • The European respiratory journal. Supplement
  • 2001
TLDR
For asymptomatic pulmonary sarcoidosis, a watch and wait approach is appropriate; treatment should mainly be considered if symptoms develop or lung function deteriorates, although there are indications of valuable alternatives. Expand
Effect of Ursodeoxycholic Acid on Granulomatous Liver Disease Due to Sarcoidosis
TLDR
A diabetic patient with sarcoid-induced anicteric cholestasis associated with high liver enzymes and unusual necrotizing granulomas accompanied by early fibrosis and septation was presented and judged to merit therapy. Expand
Treatment of sarcoidosis with infliximab.
TLDR
Infliximab appears to be an effective, safe treatment for patients with refractory sarcoidosis, including such manifestations as lupus pernio, uveitis, hepatic sarcoidsosis, and neurosarcoidotic disorders. Expand
Steroid-resistant sarcoidosis: is antagonism of TNF-α the answer?
TLDR
Although TNF-α antagonists appear relatively safe, especially when compared with conventional agents, caution is warranted in view of the increased incidence of tuberculosis, which may be a particular diagnostic challenge in patients with sarcoidosis. Expand
Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer?
TLDR
Although TNF-alpha antagonists appear relatively safe, especially when compared with conventional agents, caution is warranted in view of the increased incidence of tuberculosis, which may be a particular diagnostic challenge in patients with sarcoidosis. Expand
A concise review of pulmonary sarcoidosis.
TLDR
There is increasing evidence to support that one or more infectious agents may cause sarcoidosis, although this organism may no longer be viable in the patient, and new and more potent antiinflammatory agents have been developed. Expand
The use of low dose methotrexate in refractory sarcoidosis.
TLDR
Low dose methotrexate was used in patients with persistent, symptomatic sarcoidosis with significant improvement in objective parameters, including a greater than 15% increase in the vital capacity and improvement in chest roentgenogram. Expand
...
1
2
3
4
5
...